Lawrence Leader, DO
Cardiovascular Disease · Hattiesburg, MSNPI 1508970211
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,390 of the $40,294 with a category attached, or 90.3%. Boehringer Ingelheim accounts for 97.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $11,932 and has fallen 99.1% since, to $107 in 2025. Among cardiovascular disease clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $298.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$39K
- Novartis$397
- E.r. Squibb & Sons, L.L.C.$178
- Johnson & Johnson$146
- Abiomed$73
- Merck$67
- plus $207 from 10 others
What the payments were for
- Speaking & faculty fees$36,39090%
- Travel & lodging$1,6234%
- Food & beverage$2,2826%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 72 | $39,225 |
| Novartis | 31 | $397 |
| E.r. Squibb & Sons, L.L.C. | 5 | $178 |
| Johnson & Johnson | 8 | $146 |
| Abiomed | 3 | $73 |
| Merck | 3 | $67 |
| Boston Scientific | 2 | $40 |
| AbbVie | 2 | $30 |
| Novo Nordisk | 2 | $24 |
| Bracco Diagnostics Inc. | 1 | $20 |
| Exact Sciences | 1 | $17 |
| Medtronic | 1 | $17 |
| Stryker | 1 | $16 |
| GE HealthCare | 1 | $16 |
| Pfizer | 1 | $14 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,294 in reported general payments places this provider in the 90th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 430 | $344,347 |
| XareltoRivaroxaban | 226 | $170,943 |
| Repatha SureclickEvolocumab | 97 | $58,984 |
| EntrestoSacubitril/Valsartan | 37 | $31,678 |
| JardianceEmpagliflozin | 45 | $31,611 |
| Praluent PenAlirocumab | 32 | $15,402 |
| Repatha SyringeEvolocumab | 17 | $11,337 |
| FarxigaDapagliflozin Propanediol | 13 | $11,032 |
| Ranolazine ErRanolazine | 110 | $8,314 |
| Metoprolol Succinate | 636 | $6,943 |
| ClopidogrelClopidogrel Bisulfate | 409 | $3,614 |
| Propafenone Hcl ErPropafenone Hcl | 17 | $3,045 |
| Rosuvastatin Calcium | 300 | $2,796 |
| Atorvastatin Calcium | 352 | $2,613 |
| Propafenone Hcl | 37 | $2,538 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $344,347430 claims |
| Johnson & JohnsonXarelto | $146 | $170,943226 claims |
| NovartisEntresto | $397 | $31,67837 claims |
| Boehringer IngelheimJardiance | $39,225 | $31,61145 claims |
| AstraZenecaFarxiga | $13 | $11,03213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Hattiesburg
- Fisher CovinHattiesburg$8K
- Dharmesh PatelSouthaven$1.5M
- Barry BertoletTupelo$469K
- Donny StokesJackson$207K
- Mahmoud ZayedPascagoula$103K
- James BenslerJackson$64K
- Michael HallJackson$54K
- Hugo QuintanaPascagoula$48K
- Ediz TasanPascagoula$42K
- Matthew HannKeesler Afb$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.